Condition: Breast Cancer Prevention · Sponsor: Harokopio University
To support the development of the MELIORA digital app for the MELIORA main intervention, an initial pilot study (Data Collection Campaign, DCC) is being conducted with the three target participant groups: healthy women at increased risk of developing breast cancer (BC), BC patients, and BC survivors across the four intervention countries (Spain, Greece, Lithuania, Sweden). The planned sample size for each group is 156 healthy women at risk (defined as not meeting recommendations for a healthy lifestyle), 58 BC patients, and 86 BC survivors. Each participant is asked to test and evaluate a preliminary version of the MELIORA app over a 14-day period. The DCC takes place in the early stages of the project, as part of the intervention development phase, to inform the technical refinement and preliminary evaluation of the MELIORA digital app.
This description comes directly from the study's public registry record.
Yannis Manios, Professor · +30 2109549156 · manios@hua.gr
Always discuss trial participation with your own doctor first.
| Harokopio University | Athens, Greece | Recruiting |
| Lietuvos Sveikatos Mokslų Universitetas (Lsmu) | Kaunas, Lithuania | Recruiting |
| Pagalbos Onkologiniams Ligoniams Asociacija (Pola L T) | Kaunas, Lithuania | Recruiting |
| Fundación Para El Fomento de La Investigación Sanitaria Y Biomédica de La Comunitat Valenciana (Fisabio) | Valencia, Spain | Recruiting |
| INCLIVA - Instituto de Investigación Sanitaria | Valencia, Spain | Recruiting |
| Bröstcancerföreningen Amazona I Stockholms Län (Amazona) | Stockholm, Sweden | Recruiting |
| Karolinska Institutet | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07190066